Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Alprostadil Continuous Intravenous Infusion to Maintain Clinical Stability in Severe Heart Failure Patients

NCT00610051 is registered in ClinicalTrials.gov with Biopeutics Co., Ltd as lead sponsor.

NCT NCT00610051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00610051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Alprostadil Continuous Intravenous Infusion to Maintain Clinical Stability in Severe Heart Failure Patients
Lead sponsor
Biopeutics Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2030
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage cardiac failure, hfref - heart failure with reduced ejection fraction, nyhf class iii-iv